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Triple negative breast cancer (TNBC) has an aggressive clinical behaviour, with a poorer prognosis compared to other subtypes.
Recently, tumor-infiltrating lymphocytes (TILs) have been proposed as a predictive biomarker for a better clinical outcome and
pathological response (pR) after neoadjuvant chemotherapy (NACT) inTNBC.These data confirm the role of the immune system in
the neoplastic progression and in the response to therapy.We performed a retrospective analysis of 54 pre-NACT biopsies of TNBC
and compared both the percentage of stromal TILs and the degree of PD-L1 expression with the extent of pR to standard NACT. A
pathological complete response (pCR)was achieved in 35%of cases. Univariate analysis showed (i) a significant association between
PD-L1 expression in ≥25% of neoplastic cells and the achievement of a pCR (𝑝 = 0.024); (ii) a significantly higher frequency of
pCR in cases showing ≥50% stromal TILs (𝑝 < 0.001). However in the multivariate analysis only PD-L1 expression on tumor cells
remained significantly associated with pCR (OR = 1,13; 95% CI 1,01–1,27), suggesting that the expression of this biomarker could
be associated with a subpopulation of TNBC more likely to respond to chemotherapy. These data need to be confirmed by larger
studies.
1. Introduction
Triple negative breast cancer (TNBC) accounts for 10–20%
of all breast cancers [1]. It is often associated with high
histological grade, presence of lymphocytic infiltration, high
rate of distant metastasis, and a poorer prognosis when
compared to other breast cancer subtypes. TNBC is generally
treated with standard chemotherapy regimens, including
both anthracyclines and taxanes, either in the metastatic,
adjuvant, or neoadjuvant setting. Neoadjuvant chemotherapy
[NACT] is increasingly used in the management of this
BC subtype, with pathologic complete response (pCR) rate
ranging from 30% to 50% [2–4]. These data point to the
need of biomarkers that could be useful to identify the subset
of patients more prone to achieve a pCR. In recent reports
the presence of tumor-infiltrating lymphocytes (TILs) has
been shown to predict the response of TNBC to NACT [5–
7]. Moreover, a high number of stromal TILs is predictive
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of a more favorable outcome in this BC subset. These data
underscore the crucial role of the immune system both in
the neoplastic progression and in the response to therapy
and support the robustness of biomarkers of tumor-immune
system interplay in clinical practice [8]. The interaction
between programmed cell death protein 1 (PD-1) and its
ligand (PD-L1) represents a mechanism of immune escape
and a therapeutic target for poor-prognosis malignancies,
such as melanoma and non-small-cell lung cancer (NSCLC)
[9]. PD-1 is a transmembrane protein of 40 kDa expressed on
CD8+ and CD4+ T cells, natural killer (NK) cells, B cells,
activated monocytes, and dendritic cells [10]. It is a negative
regulator of the immune system that functions by forming a
complex with its ligands (either PDL1 or PDL2). Only limited
and contrasting data on the role of PD-L1 in breast cancer
have been reported so far. In fact, the expression of this
marker has been correlated with either a worst [11] or a better
prognosis [12].
Apart from their prognostic or predictive value, the
presence of stromal TILs and the expression of PD-L1 are
strong markers of immune activation in breast cancer and
could be involved in the response to preoperative systemic
treatment. In this study we aimed to investigate the role
of PD-L1 expression and stromal TILs in predicting the
pathological response to NACT in TNBC.We retrospectively
analyzed 54 pre-NACT biopsies and compared both the
percentage of stromal TILs and the extent of PD-L1 expres-
sion on neoplastic and inflammatory cells with the effect of
neoadjuvant chemotherapy.
2. Materials and Methods
Between January 2011 and December 2016, 54 consecutive
patients with TNBC received standard NACT (4 cycles of
doxorubicin + cyclophosphamide Q3W followed by 12 cycles
of paclitaxel weekly) at our Institutions. Clinical information,
including age, clinical stage at diagnosis, type of surgery,
and pathologic response, was extracted from the institutional
databases.
2.1. Evaluation of Stromal Tumor-Infiltrating Lymphocytes.
Pre-therapy biopsies were retrieved from the Pathology
Departments at the Sapienza University Teaching Hospital
and the San Giovanni-Addolorata Hospital. Hematoxylin-
eosin stained slides were blindly re-evaluated for the presence
of stromal tumor-infiltrating lymphocytes (TILs) according
to a previously published method [13]. Briefly, TILs were
quantified as a percentage of the stromal area of the tumor
and expressed as a continuous parameter.
2.2. Evaluation of PD-L1 Expression and Immunophenotyping
of the Inflammatory Infiltrate. Serial sections were obtained
from each paraffin block for (i) immunohistochemical eval-
uation of PD-L1 expression on both neoplastic and inflam-
matory cells and (ii) immunophenotyping of the inflamma-
tory infiltrate. PD-L1 immunostains were performed with
one of the antibody clones approved for diagnostic assay
(SP142, rabbit IgG, dilution 1 : 200, catalog #M4420; Spring
Bioscience, Pleasanton, CA) [14] at 1 : 100 dilution, using an
automated immunostainer (BenchmarkXT,VentanaMedical
System, Tucson, AZ, USA) with the Optiview DAB IHC
detection kit (Ventana Medical Systems, Tucson, Arizona,
USA) according tomanufacturer’s instructions. Relevant pos-
itive controls (human tonsils and placenta) were used for each
run of staining. Negative controls were obtained by omitting
the primary antibody.The expression of PD-L1 was evaluated
separately on all tumor cells and inflammatory infiltrates.
A minimum of 200 neoplastic cells were present in each
biopsy sample. A positive stain was defined as the presence
of membrane staining, either strong or weak, complete or
incomplete, in a percentage of cells≥ 1%, that is, the threshold
reported for clinical response to PD-L1 inhibitors in non-
small-cell lung carcinoma and has also been reported in
breast carcinoma [15, 16]. For each biopsy, both the intensity
of membrane staining (scored as 1+ weak, 2+ moderate, and
3+ strong) and the percentage of positive neoplastic cells were
recorded, while only the percentage of positive inflammatory
cells was evaluated.
Immunophenotyping of the inflammatory infiltrates was
carried out with the following antibodies: CD3 for T lympho-
cytes (Roche, 1 : 100); CD4 (1 : 40) for the helper T subset; CD8
for the cytotoxic T subset (1 : 100); CD20 for B lymphocytes
(1 : 200) CD68 for macrophages (1 : 100), and N-CAM (1 : 100)
(all from Novocastra, Newcastle, UK). Four images at 20x
original magnification (accounting for one mm2 of tumor
field) were acquired from the areas of maximum inflamma-
tory infiltrate by theNIS ElementsViewermounted on aZeiss
Axioskop 2 microscope. The number of positive cells/mm2
for each antibodywas thenmanually counted on the acquired
images.
2.3. Evaluation of the Pathologic Response to NACT. The
degree of pathologic response of each patient to NACT was
obtained from the pathology reports. A complete response
was defined as the complete disappearance of invasive tumor
cells from breast tissue and regional lymph nodes, regardless
of the presence of residual ductal carcinoma in situ (ypT0/is,
ypN0) [17, 18].
2.4. Statistical Analysis. In the descriptive analysis, quantita-
tive variables were described as mean and range, while qual-
itative variables were reported as number and percentage.
Univariate associations between clinicopathological features
and pCR were evaluated using the 𝜒2 test or Fisher’s exact
test, when appropriate. To take into account the effects of all
variables on pCR, multivariate analysis were performed by a
multivariate logistic regression to estimate the adjuster Odds
Ratios (ORs). Statistical significance was set at 𝑝 < 0.05. All
analyses were performed using SAS 9.4 (SAS Institute Inc.,
Cary, NC, USA).
3. Results
Clinicopathological features of the 54 patients are detailed
in Table 1. Briefly, the mean age at diagnosis was 50 years
(range 28–75). In 87% of cases the pre-NACT tumor diameter
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Table 1: Clinicopathological features of the study population.
Characteristics Number ofpatients (%)
Age (y)
≤50 30 (55%)
>50 24 (45%)
Pre-NACT tumor size (cT)
≤2 cm 7 (13%)
>2 cm 47 (87%)
Pre-NACT nodal status (cN)
Positive 24 (45%)
Negative 30 (55%)
Histotype
Ductal 51 (94%)
Lobular 1 (2%)
Others 2 (4%)
Nuclear grade
Grades 1-2 0
Grade 3 54 (100%)
Ki-67
<50% 14 (26%)
≥50% 40 (74%)
Post-NACT surgery
Mastectomy 30 (55%)
Segmental mastectomy 24 (45%)
Complete pathological response (pCR) to NACT 19 (35%)
was larger than 2 cm. Axillary node involvement, assessed
by echography and confirmed by fine needle aspiration
cytology, was present in 24 patients (45%).Themost common
histologic subtype was ductal carcinoma of no special type
(94% of cases). All tumors were of high nuclear grade (G3)
with a proliferation index ≥ 50% in the large majority of cases
(74%).
After NACT 30 patients (55%) underwent mastectomy
and 24 (45%) had conservative breast surgery, A pCR was
achieved in 19 patients (35%).
3.1. Tumor-Infiltrating Lymphocytes and Immunophenotype
of the Inflammatory Infiltrates in Pre-NACT Biopsies. The
results of stromal TILs evaluations are detailed in Table 2.
Briefly, stromal TILs were present in 51 pre-NACT biopsies
(95%), with percentages ranging from 2 to 80% (Figures 1(a)
and 1(b)). Twenty-four cases (45.5%) had 50% or greater
stromal TILs (high TILs) and were accordingly classified
as lymphocyte predominant breast cancer (LPBC) [13].
Immunophenotyping of the inflammatory infiltrates revealed
a predominance of CD3+ T cells in all biopsy samples. In 36
biopsies (70%) the most represented was the CD8+ subset,
followed by the CD4+ subset (27%). Intriguingly, NK cells
were absent in 96% of biopsies.
3.2. Expression of PD-L1 onNeoplastic and Inflammatory Cells.
Membrane staining of neoplastic cells was present in 19 pre-
NACT biopsies (35%), with an extent ranging from 1 to 90%
(Figures 1(c) and 1(d)). In over 95% of these biopsies (18/19)
the percentage of PD-L1 positive tumor cells did not exceed
50%. The membrane stain scored 3+ in 8/19 cases (42%),
2+ in 5/19 (26%), and 1+ in 6/19 (32%). PD-L1 staining of
inflammatory cells was present in themajority of biopsies (44
cases, 81%) (Figures 1(e) and 1(f)).
Univariate analysis showed a significant association
between the presence of high stromal TILS and the expression
of PD-L1 on ≥25% of tumor cells (𝑝 = 0.008) and ≥10%
of inflammatory cells (𝑝 = 0.002); this association was
independent from the prevalent lymphocyte subset (CD8+ or
CD4+), and from the CD8/ CD4 ratio.
3.3. Comparison of Histologic and Immunohistochemical Data
with the Response to NACT. A pCR was achieved in 19
patients (35%). Univariate analysis (Table 2) showed a signif-
icant association between the expression of PD-L1 in ≥25%
of neoplastic cells and pCR (𝑝 = 0.02). The presence of
pCR was also significantly more frequent in cases showing
features of LPBC (with high TILs) in the pre-NACT biopsies
(𝑝 < 0.001). Moreover, pCR was achieved in 100% of patients
showing both high TILs and expression levels of PD-L1 ≥
25% in neoplastic cells in the pre-NACT biopsies (𝑝 = 0.011,
Table 3).
At multivariate analysis (Table 4), only PD-L1 expression
on tumor cells remained significantly associated with pCR
(𝑝 = 0.038) with OR of 1,13 (95% CI 1,01–1,27).
4. Discussion
The immune system is strongly involved both in the tumor
surveillance and in the pathogenesis of breast cancer. More-
over, preexisting immunity against tumor cells is a crucial
factor that influences the response to chemotherapy. It is now
believed that preexisting antitumor immunity is activated or
enhanced during the initial cycle of chemotherapy. During
the subsequent cycles, together with incoming acquired drug
resistance of the tumor cells, the onset of immune resistance
mechanisms impairs the efficacy of treatment [19, 20].
Due to the high histological grading andmutational load,
alongwith the activation of large amounts of genes implicated
in immune function, TNBC seems to be the subtype more
likely associated with immune system involvement. Thus,
the identification of novel immunological prognostic and
predictive biomarkers would be useful to guide the choice of
the most appropriate treatment, as well as the optimal timing
of surgery, especially in the neoadjuvant setting.
Either the presence of stromal TILs or the expression of
PD-L1 is being actively investigated as prognostic biomarkers
in TNBC. This subset of breast cancer has an aggressive
clinical and biological behaviour, with higher risk for early
recurrences and a poorer prognosis as compared to the
other BC subtypes. However, in the neoadjuvant setting, the
achievement of a pCR after NACT is associated with long-
term survival. In this study, we investigated the hypothesis
that the presence of high stromal TILs and the expression
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Figure 1: Evaluation of stromal TILs and PD-L1 expression in TNBC core biopsies. (a)-(b): low (a) and high (b) level of stromal tumor-
infiltrating lymphocytes (haematoxylin and eosin, original magnification ×10). (c)-(d): membranous PD-L1 stain in scattered (c) and diffuse
neoplastic cells (d) (PD-L1 immunohistochemical stain, original magnification ×20). (e)-(f): membranous PD-L1 stain in scattered (e) and
diffuse inflammatory cells (f) (PD-L1 immunohistochemical stain, original magnification ×20).
of PD-L1, both markers of immune activation in the tumor
microenvironment, could be associated with the rate of pCR
in TNBC.
We evaluated pre-NACT core biopsies, which proved to
be qualitatively and quantitatively adequate for our analysis.
In our study population, 35% of patients achieved a pCR,
which is in line with recently published literature [21, 22].
On microscopic evaluation of pre-NACT core biopsies,
tumor cell expression of PD-L1 was observed in 35% of cases,
although at low levels (≥1% <25% in 15/19 biopsies, 79%).
Our observation on a pure sample of TNBC confirms the
results of Dill et al. [16] who analyzed a large number of BC
with various histologic subtypes, showing the highest rate of
PD-L1 expression (32%) in TNBC, with only 5% with diffuse
expression on tumor cells (>50%).
PD-L1 expression, both on neoplastic and inflammatory
cells, was significantly associated with high stromal TILs.
Our observation extends the results reported by Mori et al.
[23], which showed a significant association between PD-
L1 expression on tumor cells and percentage of stromal
TILs on surgical breast specimens, and confirms the parallel
behaviour of these immune biomarkers in TNBC.The limited
BioMed Research International 5
Table 2: Association between stromal TILs, the expression of PD-L1 on tumor cells and inflammatory infiltrate, Ki-67 value, cT, cN, and pCR
in the univariate analysis.
𝑁 (%) pCR
𝑁∘ 𝑝 value
Stromal TILs
Absent/low 32 (59%) 8
<0.001
High 22 (41%) 11
PD-L1 on tumor cells
0% 35 (65%) 11
≥1–<25% 15 (28%) 4
≥25% 4 (7%) 4 0.024
PD-L1 on inflammatory cells
Negative 10 (19%) 3 ns
Positive 44 (81%) 15
Ki-67
<50% 14 (26%) 4 ns
≥50% 40 (74%) 15
cT
T1 7 (13%) 3 ns
T2–T4 47 (87%) 16
cN
Negative 30 (56%) 13 ns
Positive 24 (44%) 6
Table 3:The achievement of pCR according to levels of both stromal
TILs and PD-L1 expression on neoplastic cell membranes (low
TILs/low PD-L1; high TILs/low PD-L1; low TILs/high PD-L1; high
TILs/high PD-L1).
PD-L1 on neoplastic cells
TILs <25% ≥25%
pt pt pCR pt pCR
Low 32 32 25% 0
𝑝 = 0.011
High 22 18 39% 4 100%
amount of published reports in pure cohorts of TNBC seems
to suggest a favorable prognostic role of PD-L1, despite
some discrepancies. Mori et al. [23] demonstrated that the
interaction between TILs and PD-L1 correlates with a better
clinical outcome. However, when high PD-L1 expression is
associated with low levels of stromal TILs the prognosis
is poor [24]. In the study of Beckers et al. [25] PD-L1,
although associated with a better outcome, failed to show an
independent prognostic role in this subset of tumors. These
partial discrepancies could be explained by differences in the
choice of clinical outcomes, in the methods of evaluation of
PD-L1 expression on neoplastic cells (membranous versus
cytoplasmic) and the cut-off values adopted, and in the
antibodies used and the type of sample evaluated (core
biopsies versus surgical samples).
There are only limited data on the predictive value of these
two biomarkers in TNBC.We found that in this breast cancer
subtype the concomitant expression of stromal TILs and PD-
L1 on tumor cells membranes was significantly associated
with pCR. According to our results, a cut-off of PD-L1
membrane expression on ≥25% of neoplastic cells in pre-
neoadjuvant biopsies predicted pCR for TNBC, regardless of
staining intensity. On the contrary, the predictive role of TILs
showed only a limited power and no statistical association
on multivariate analysis. In light of the preliminary results
of the KEYNOTE 173 phase II trial [26], reporting a 90%
pCR rate in TNBC treated in this setting with the adjunct
of pembrolizumab to standard chemotherapy, we hypothesize
that TNBC expressing PD-L1 in less than 25% of tumor cells
could represent the subset most likely to benefit from this
association.
Immunophenotyping of tumor inflammatory microenvi-
ronment revealed an excess of CD8+with a ratio of CD8/CD4
> 1, in line with previous reports [27, 28], although this
observation did not reach statistical significance probably due
to our limited sample size. Additionally, we found negligible
amounts of NK cells in pre-NACT biopsies, although we
cannot exclude the fact that their level could have been
increased after the first cycle of chemotherapy due to tumor
cells death and the release tumor associated antigens.
In conclusion, we showed that a cut-off value of PD-L1
in ≥25% of tumor cells predicts pCR in TNBC and to our
knowledge our study is the first dealing with an exclusive
population of TNBC cases. A possible explanation for our
observation is that PD-L1 expression could be associated with
a subpopulation of TNBC with a more aggressive behaviour,
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Table 4: Association between the expression of PD-L1 on neoplastic cells and inflammatory infiltrate, stromal TILs, Ki67, clinical T, clinical
N, and pCR in the multivariate analysis.
𝑁 (%) pCR
𝑁 (%) 𝑝 value ORR (CI)
Stromal TILs
Low 32 (60%) 8 (25%) 0.5 1,61 (0,40–6,52)
High 22 (40%) 11 (50%)
PD-L1 on tumor cells
0% 35 (65%) 11 (31%)
0.038 1,13 (1,01–1,27)1–25% 15 (28%) 4 (27%)
≥25% 4 (7%) 4 (100%)
PD-L1 on inflammatory cells
Negative 10 (18%) 3 (30%) 0.058 0,09 (0,01–1,08)
Positive 44 (82%) 15 (34%)
Ki-67
<50% 14 (26%) 4 (28%) 0.054 1,05 (1–1,09)
≥50% 40 (74%) 15 (37%)
Clinical T
T1 7 (13%) 3 (43%) 0.8 0,8 (0,08–8,09)
T2–T4 47 (87%) 16 (34%)
Clinical N
Negative 30 (55%) 13 (43%) 0.27 0,47 (0,12–1,82)
Positive 24 (45%) 6 (25%)
likely to respond to chemotherapy. Further studies with larger
number of cases are warranted to confirm our findings.
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